Source: ERJ Open Res, 6 (4) 00405-2020; 10.1183/23120541.00405-2020



Rating:

Share or cite this content

Citations should be made in the following way:
Rahul Kumar, Michael H. Lee, Claudia Mickael, Biruk Kassa, Qadar Pasha, Rubin Tuder, Brian Graham. Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19. ERJ Open Res, 6 (4) 00405-2020; 10.1183/23120541.00405-2020

Member's Comments

No comment yet.

Related content which might interest you: Does acute and persistent metabolic dysregulation in COVID-19 point to novel biomarkers and future therapeutic strategies? Source: Eur Respir J, 59 (2) 2102417; 10.1183/13993003.02417-2021 Year: 2022 Clinical implications and novel therapies Source: International Congress 2018 – Accelerated ageing in lungs Year: 2018 Clinical implications and opportunities for new drug therapies Source: Annual Congress 2008 - Deadly networks: disease-causing protein and DNA modifications Year: 2008 COVID-19 conundrum: clinical phenotyping based on pathophysiology as a promising approach to guide therapy in a novel illness Source: Eur Respir J, 56 (2) 2002135; 10.1183/13993003.02135-2020 Year: 2020 COPD mechanisms: novel aspects and implications for new therapies Source: ERS Live 2007 Year: 2007 Potential of regulatory T-cell-based therapies in the management of severe COVID-19 Source: Eur Respir J, 56 (3) 2002182; 10.1183/13993003.02182-2020 Year: 2020 Lots of promising targets and biomarkers, but how can we deliver the next generation of severe asthma trials? Source: International Congress 2019 – Beyond T2 mechanisms in asthma: who are the other players? Year: 2019 Current and future preventive and treatment strategies in CLAD Source: International Congress 2015 – When chronic inflammation drives fibrosis: a lesson from lung transplantation Year: 2015 Genetic studies as a tool for identifying novel potential targets for treatment of COPD Source: Eur Respir J, 50 (5) 1702042; 10.1183/13993003.02042-2017 Year: 2017 Recommendations of new therapies for severe asthma and the future Source: Annual Congress 2013 –ERS/ATS Task Force report on severe asthma Year: 2013 Advances in treatment of complex lung disease: will targeted therapy with anticalins be clinically applied in the near future? Source: International Congress 2019 – Inhaled medicines and biological therapies in the current era of systemic treatments Year: 2019 Value of animal models. Lessons learnt from another therapeutic area: implications for respiratory disease Source: Annual Congress 2007 - PG11 - Translation of animal models to human airway disease Year: 2007 The future: treating specific endotypes Source: International Congress 2015 – PG2 Asthma and COPD Year: 2015 The future: treating specific endotypes Source: International Congress 2016 – PG1 Asthma and chronic obstructive pulmonary disease Year: 2016 Novel targets and emerging therapies in MPM Source: ERS Skills course: Multi-disciplinary care in thoracic oncology Year: 2019 Targeting the arginase pathway: potential developments as new avenues for treatment Source: Annual Congress 2004 - Arginase: a novel target and marker for asthma? Year: 2004 Characterisation of clinical phenotypes is mandatory for the development of new drugs Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD Year: 2014 Halotherapy and Covid-19: an oppinion for a possible future prevention approach Source: Virtual Congress 2021 – COVID – 19: treatments and predictive factors Year: 2021